Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

OncoImmunology

Volumn 5, Issue 9, 2016, Pages

  Liniker, E ^a   Menzies, A M ^a,b,c   Kong, B Y ^d   Cooper, A ^d   Ramanujam, S ^a   Lo, S ^a   Kefford, R F ^a,d,e   Fogarty, G B ^a,c   Guminski, A ^a,b,c   Wang, T W ^d   Carlino, M S ^a,d   Hong, A ^a,c   Long, G V ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Mater Hospital   (Australia)

^d Crown Princess Mary Cancer Centre Westmead   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

Anti pd 1 antibody; immunotherapy; melanoma; radiotherapy

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN EDEMA; CLINICAL OUTCOME; DIARRHEA; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG SAFETY; ENDOCRINE DISEASE; FEMALE; FEVER; HUMAN; LIVER TOXICITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; RADIATION NECROSIS; RASH; SOFT TISSUE; STEREOTACTIC RADIOSURGERY; STEVENS JOHNSON SYNDROME; VITILIGO; XEROSTOMIA;

EID: 84986290400     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1214788     Document Type: Article

References (37)

1. H.Borghaei, L.Paz-Ares, L.Horn, D.R.Spigel, M.Steins, N.E.Ready, L.Q.Chow, E.E.Vokes, E.Felip, E.Holgado et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med 2015; 373:1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
2. R.J.Motzer, B.I.Rini, D.F.McDermott, B.G.Redman, T.M.Kuzel, M.R.Harrison, U.N.Vaishampayan, H.A.Drabkin, S.George, T.F.Logan et al. Nivolumab for metastatic renal cell carcinoma:results of a randomized phase II trial. J Clin Oncol 2015; 33:1430-7; PMID:25452452; http://dx.doi.org/10.1200/JCO.2014.59.0703
3. J.Brahmer, K.L.Reckamp, P.Baas, L.Crino, W.E.Eberhardt, E.Poddubskaya, S.Antonia, A.Pluzanski, E.E.Vokes, E.Holgado et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
4. A.Ribas, I.Puzanov, R.Dummer, D.Schadendorf, O.Hamid, C.Robert, F.S.Hodi, J.Schachter, A.C.Pavlick, K.D.Lewis et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002):a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908-18; PMID:26115796; http://dx.doi.org/10.1016/S1470-2045(15)00083-2
5. C.Robert, J.Schachter, G.V.Long, A.Arance, J.J.Grob, L.Mortier, A.Daud, M.S.Carlino, C.McNeil, M.Lotem et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Eng J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
6. J.S.Weber, S.P.D'Angelo, D.Minor, F.S.Hodi, R.Gutzmer, B.Neyns, C.Hoeller, N.I.Khushalani, W.H.Miller, Jr, C.D.Lao et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
7. C.T.Garnett, C.Palena, M.Chakraborty, K.Y.Tsang, J.Schlom, J.W.Hodge. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64:7985-94; PMID:15520206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1525
8. E.A.Reits, J.W.Hodge, C.A.Herberts, T.A.Groothuis, M.Chakraborty, E.K.Wansley, K.Camphausen, R.M.Luiten, A.H.de Ru, J.Neijssen et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71; PMID:16636135; http://dx.doi.org/10.1084/jem.20052494
9. S.Demaria, B.Ng, M.L.Devitt, J.S.Babb, N.Kawashima, L.Liebes, S.C.Formenti. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-70; PMID:14967443; http://dx.doi.org/10.1016/j.ijrobp.2003.09.012
10. S.Demaria, N.Kawashima, A.M.Yang, M.L.Devitt, J.S.Babb, J.P.Allison, S.C.Formenti. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862
11. S.S.Park, H.Dong, X.Liu, S.M.Harrington, C.J.Krco, M.P.Grams, A.S.Mansfield, K.M.Furutani, K.R.Olivier, E.D.Kwon. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015; 3:610-9; PMID:25701325; http://dx.doi.org/10.1158/2326-6066.CIR-14-0138
12. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Eng J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
13. E.F.Stamell, J.D.Wolchok, S.Gnjatic, N.Y.Lee, I.Brownell. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phy 2013; 85:293-5; PMID:22560555; http://dx.doi.org/10.1016/j.ijrobp.2012.03.017
14. C.Twyman-Saint Victor, A.J.Rech, A.Maity, R.Rengan, K.E.Pauken, E.Stelekati, J.L.Benci, B.Xu, H.Dada, P.M.Odorizzi et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292
15. K.A.Ahmed, D.G.Stallworth, Y.Kim, P.A.Johnstone, L.B.Harrison, J.J.Caudell, H.H.Yu, A.B.Etame, J.S.Weber, G.T.Gibney. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2016; 27:434-41; PMID:26712903; http://dx.doi.org/10.1093/annonc/mdv622
16. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
17. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Eng J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
18. K.Tye, H.H.Engelhard, K.V.Slavin, M.K.Nicholas, S.J.Chmura, Y.Kwok, D.S.Ho, R.R.Weichselbaum, M.Koshy. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neuro-Oncol 2014; 117:321-7; PMID:24504500; http://dx.doi.org/10.1007/s11060-014-1391-8
19. G.B.Fogarty, A.Hong, K.Dolven-Jacobsen, C.H.Reisse, B.Burmeister, L.H.Haydu, H.Dhillon, V.Steel, B.Shivalingam, K.Drummond et al. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes 2015; 8:192; PMID:25952979; http://dx.doi.org/10.1186/s13104-015-1153-5
20. M.Kocher, R.Soffietti, U.Abacioglu, S.Villa, F.Fauchon, B.G.Baumert, L.Fariselli, T.Tzuk-Shina, R.D.Kortmann, C.Carrie et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-41; PMID:21041710; http://dx.doi.org/10.1200/JCO.2010.30.1655
21. D.W.Andrews, C.B.Scott, P.W.Sperduto, A.E.Flanders, L.E.Gaspar, M.C.Schell, M.Werner-Wasik, W.Demas, J.Ryu, J.P.Bahary et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-72; PMID:15158627; http://dx.doi.org/10.1016/S0140-6736(04)16250-8
22. T.Korytko, T.Radivoyevitch, V.Colussi, B.W.Wessels, K.Pillai, R.J.Maciunas, D.B.Einstein. 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 2006; 64:419-24; PMID:16226848; http://dx.doi.org/10.1016/j.ijrobp.2005.07.980
23. B.J.Blonigen, R.D.Steinmetz, L.Levin, M.A.Lamba, R.E.Warnick, J.C.Breneman. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2010; 77:996-1001; PMID:19783374; http://dx.doi.org/10.1016/j.ijrobp.2009.06.006
24. G.Minniti, E.Clarke, G.Lanzetta, M.F.Osti, G.Trasimeni, A.Bozzao, A.Romano, R.M.Enrici. Stereotactic radiosurgery for brain metastases:analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011; 6:48; PMID:21575163; http://dx.doi.org/10.1186/1748-717X-6-48
25. S.Du Four, S.Wilgenhof, J.Duerinck, A.Michotte, A.Van Binst, M.De Ridder, B.Neyns. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 2012; 48:3045-51; PMID:22727601; http://dx.doi.org/10.1016/j.ejca.2012.05.016
26. S.Du Four, A.Hong, M.Chan, M.Charakidis, J.Duerinck, S.Wilgenhof, W.Wang, L.Feng, A.Michotte, M.Okera et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Reports Oncol Med 2014; 2014:417913; PMID:25105043; http://dx.doi.org/10.1155/2014/417913
27. A.P.Kiess, J.D.Wolchok, C.A.Barker, M.A.Postow, V.Tabar, J.T.Huse, T.A.Chan, Y.Yamada, K.Beal. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab:safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92:368-75; PMID:25754629; http://dx.doi.org/10.1016/j.ijrobp.2015.01.004
28. K.R.Patel, S.Shoukat, D.E.Oliver, M.Chowdhary, M.Rizzo, D.H.Lawson, F.Khosa, Y.Liu, M.K.Khan. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2015 May 16. (Epub ahead of print); http://dx.doi.org/10.1097/COC.0000000000000199.
29. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
30. V.Gondi, S.L.Pugh, W.A.Tome, C.Caine, B.Corn, A.Kanner, H.Rowley, V.Kundapur, A.DeNittis, J.N.Greenspoon et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase II multi-institutional trial. J Clin Oncol 2014; 32:3810-6; PMID:25349290; http://dx.doi.org/10.1200/JCO.2014.57.2909
31. T.Z.Vern-Gross, A.Kowal-Vern. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy:a literature review. Am J Clin Oncol 2014; 37:506-13; PMID:22892429; http://dx.doi.org/10.1097/COC.0b013e31825d5835
32. M.Z.Dewan, A.E.Galloway, N.Kawashima, J.K.Dewyngaert, J.S.Babb, S.C.Formenti, S.Demaria. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265
33. S.J.Dovedi, A.L.Adlard, G.Lipowska-Bhalla, C.McKenna, S.Jones, E.J.Cheadle, I.J.Stratford, E.Poon, M.Morrow, R.Stewart et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74:5458-68; PMID:25274032; http://dx.doi.org/10.1158/0008-5472.CAN-14-1258
34. J.P.Knisely, J.B.Yu, J.Flanigan, M.Sznol, H.M.Kluger, V.L.Chiang. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-33; PMID:22702482; http://dx.doi.org/10.3171/2012.5.JNS111929
35. D.Schaue, J.A.Ratikan, K.S.Iwamoto, W.H.McBride. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83:1306-10; PMID:22208977; http://dx.doi.org/10.1016/j.ijrobp.2011.09.049
36. A.M.Grimaldi, E.Simeone, D.Giannarelli, P.Muto, S.Falivene, V.Borzillo, F.M.Giugliano, F.Sandomenico, A.Petrillo, M.Curvietto et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunol 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
37. E.A.Eisenhauer, P.Therasse, J.Bogaerts, L.H.Schwartz, D.Sargent, R.Ford, J.Dancey, S.Arbuck, S.Gwyther, M.Mooney et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026